Skip to main content
. Author manuscript; available in PMC: 2006 Jan 1.
Published in final edited form as: Anesth Analg. 2005 Jan;100(1):169–174. doi: 10.1213/01.ANE.0000138037.19757.ED

Table 3.

Adverse events.

Nefopam (n = 22) Ketamine (n = 22) Control (n = 21) P
Nausea or Vomiting 12 8 4 NS
Tachycardia 8 2 3 < 0.005
Profuse Sweating 4 0 0 < 0.05
Dry Mouth 4 0 1 NS
Dysphoria 0 1 0 NS
Diplopia 0 2 2 NS
Dizziness 1 4 1 NS

Results presented as number of patients. Tachycardia and profuse sweating were most frequent in the Nefopam group.